- Dosing has commenced in a Phase 1 clinical trial evaluating the safety and tolerability of Palatin Technologies' (NYSE:PTN) lead candidate PL-8177 in healthy volunteers. Top-line data are expected in Q3.
- PL-8177 is a selective melanocortin receptor 1 (MC1r) agonist peptide. In other words, it is a modulator of the melanocortin system which plays a key role in appetite and energy expenditure. It is being developed for the treatment of ulcerative colitis and other inflammatory bowel disorders.
- Previously: Palatin to start clinical development of UC candidate PL-8177; shares up 6% premarket (Jan. 3)
Early-stage study underway assessing Palatin's lead candidate PL-8177
Recommended For You
About PTN Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
PTN | - | - |
Palatin Technologies, Inc. |